




Company Profile

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis.



Management

David Cory, RPh, MBA
President and Chief Executive Officer

Ingrid Choong, PhD
Director, Chemistry

Jeffrey Glenn, MD, PhD
Scientific Founder

Kevin Kaster, JD
Vice President of Patents and Licensing

Curt Scribner, MD
Vice President, Regulatory

Board of Directors

David Cory, RPh, MBA
President and Chief Executive Officer,
Eiger BioPharmaceuticals

Edgar Engleman, MD
Managing Partner, Vivo Ventures

Jeffrey Glenn, MD, PhD
Scientific Founder, Associate
Professor, Stanford University

Nina Kjellson
General Partner, InterWest Partners

Paul Truex, MBA
President and Chief Executive Officer,
Anthera Pharmaceuticals

Current Programs

EBP921
HDV Proof of Concept Multicenter International Study
Enrolling

EBP994
HDV Proof of Concept Study
Enrolling

EBP1597
HCV NS4B-AH Inhibitor
IND Enabling Studies Ongoing

Eiger BioPharmaceuticals, Inc.
PO Box 430
San Carlos, CA 94070
www.eigerbio.com